Combined human growth hormone and lactulose for prevention and treatment of multiple organ dysfunction in patients with severe chronic hepatitis B

Table 2 Effects of rhGH on GH-IGF axis in patients with severe chronic hepatitis B (mean±SD).

Marker of GH-IGF axis	Pretreatment (n = 15)	2-wk treatment (n = 15)
GH (ng/mL)	10.4±7.6	6.2±8.1a
IGF-1 (mg/mL)	6.3±4.5	8.8±6.7
IGFBP1 (ng/mL)	56.8±47.2	89.7±50.3a
IGFBP3 (mg/mL)	3.5±1.7	5.1±3.4

^aP<0.05 vs pretreatment.